Equillium, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EQ Nasdaq 2836 www.equilliumbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Equillium, Inc.

Integrated Rewards Expands Offer Network into Everyday Spend Categories Like Fuel, Hotel and Grocery - Jul 21st, 2026 6:00 am
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504 - Jun 10th, 2026 11:45 am
EQ Works Expands ClearLake Platform with AI-Powered Audience Segments - Jun 4th, 2026 6:00 am
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1 - May 29th, 2026 9:03 am
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis - May 20th, 2026 2:05 pm
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights - May 13th, 2026 2:01 pm
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 2:42 pm
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event - Apr 20th, 2026 2:05 pm
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists - Apr 8th, 2026 6:30 am
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights - Mar 25th, 2026 2:05 pm
Here’s What Roth Capital Thinks of Equillium (EQ) Stock - Mar 24th, 2026 3:38 pm
Equillium Announces $35 Million Financing with RA Capital Management - Mar 13th, 2026 6:00 am
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start - Feb 13th, 2026 11:28 am